News Release

<< Back

Heron Therapeutics Appoints Kimberly J. Manhard as Executive Vice President of Drug Development

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan. 28, 2016-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today announced the appointment of Kimberly J. Manhard as Executive Vice President of Drug Development. Ms. Manhard joins the Company today and will report to Barry D. Quart, Pharm.D., Chief Executive Officer of Heron.

“Kimberly has played an important role at Heron since joining our Board of Directors in January 2014, so we are delighted that she will be joining the Company as a permanent member of our leadership team,” commented Dr. Quart. “Kimberly brings to her role at Heron over 25 years of drug development, regulatory affairs and pharmaceutical operations experience, which will be invaluable to the Company as we move forward with the development of our exciting pipeline of product candidates targeting cancer or pain.”

Since 2008, Ms. Manhard has served as the Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc., a wholly-owned subsidiary of AstraZeneca PLC. In her role at Ardea, Ms. Manhard was instrumental in the development and December 2015 regulatory approval of Zurampic® (lesinurad), by the U.S. Food and Drug Administration (FDA) for the treatment of hyperuricemia associated with gout. Ms. Manhard joined Ardea in 2006, overseeing general corporate operations. Ardea Biosciences, Inc. was acquired by AstraZeneca PLC for $1.26 billion in June 2012. Since its sale, Ms. Manhard took on the additional roles of Ardea's Corporate Compliance Officer and as a director of Ardea Biosciences Limited. Prior to her tenure at Ardea, Ms. Manhard was President of her own consultancy firm, Vice President of Regulatory Affairs for Exelixis, Inc., and held multiple regulatory positions at Agouron Pharmaceuticals, Inc., a Pfizer Inc. company, supporting the development and commercialization of anticancer and antiviral products, including Viracept® (nelfinavir). She was also previously with Bristol Myers Squibb Company in regulatory affairs, responsible for oncology compounds, including Taxol® (paclitaxel) and infectious disease compounds, including Videx® (didanosine) and Zerit® (stavudine).

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. Heron’s goal is to build on therapeutics with well-known pharmacology by improving their tolerability and efficacy as well as broadening their potential field of use. For more information, visit www.herontx.com.

Forward Looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, those associated with: whether the U.S. Food and Drug Administration (FDA) completes its review within the anticipated time period, whether the FDA approves the SUSTOL NDA as submitted or supports as broad of a labeled indication for SUSTOL as requested, the potential market opportunity for SUSTOL and expected timing of the commercial launch, the progress in the research and development of HTX-019, HTX-011 and our other programs, including the timing of preclinical, clinical, and manufacturing activities, safety and efficacy results from our studies that may not justify the pursuit of further development of our product candidates, acceptance of SUSTOL and new products generally, our financial position and our ability to raise additional capital to fund operations, if necessary, or to pursue additional business opportunities, strategic business alliances we may pursue or the potential acquisition of products or technologies, and our ability to grow our organization to sustain the commercial launch for SUSTOL, and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Source: Heron Therapeutics, Inc.

Investor Relations Contact:
Jennifer Capuzelo, 858-703-6063
Associate Director, Investor Relations
jcapuzelo@herontx.com
Corporate Contact:
Barry D. Quart, Pharm D., 650-366-2626
Chief Executive Officer